



Commercial & HealthCare Exchange PA Criteria *Effective: June 3, 2020*

Prior Authorization: Xcopri

Products Affected: Xcopri (cenobamate) oral tablets

Medication Description: Xcopri is approved for the treatment of partial onset seizures in adult patients. The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate reduces repetitive neuronal firing by inhibiting voltage-gated sodium currents and is a positive allosteric modulator of the gamma-aminobutyric acid (GABA-A) ion channel.

Covered Uses: Partial-onset seizure

Exclusion Criteria: Familial Short QT syndrome

Required Medical Information:

- 1) Diagnosis
- 2) Previous therapies tried and failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Xcopri is being prescribed by, or in consultation with, a neurologist

Coverage Duration: 12 months

Other Criteria:

- A. Patient must have a diagnosis of partial-onset seizures; **AND**
- B. The patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, levetiracetam, carbamazepine, lamotrigine, topiramate, phenytoin, or oxcarbazepine)

References:

1. Xcopri [product insert]. SK Biopharmaceuticals. Paramus, NJ. November 2019.
2. Xcopri. Lexicomp Online [Internet database], Hudson, Ohio: Wolters Kluwer Health, Inc; May 20, 2020.



Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	06/03/2020

